This prompt template is designed for research teams, clinical analysts, and pharmacovigilance professionals who need to query clinical trial protocols, results summaries, adverse event reports, and regulatory filings. The prompt enforces strict separation of primary and secondary endpoints, requires trial phase context in every answer, and mandates statistical significance notes when numerical results are cited. Use this prompt when your retrieval pipeline returns chunks from ClinicalTrials.gov records, FDA review documents, published trial manuscripts, or internal clinical study reports. The prompt assumes retrieved context contains structured trial data and will refuse to answer when evidence is insufficient.
Prompt
Clinical Trial Data Q&A Prompt Template

When to Use This Prompt
Defines the ideal user, required context, and strict boundaries for deploying the Clinical Trial Data Q&A prompt in a production RAG pipeline.
Do not use this prompt for patient-level clinical decision support or diagnostic reasoning. Those workflows require separate prompts with explicit human-review gates and medical disclaimer language. This prompt is also unsuitable for general biomedical literature review without trial-specific structure, as it expects fields like enrollment counts, arm descriptions, and p-values to be present in the retrieved context. Before deploying, verify that your retrieval pipeline consistently surfaces trial registry entries, results databases, or regulatory documents rather than press releases or news summaries, which lack the statistical rigor this prompt demands.
The prompt is designed to fail safely: it will output ANSWERABLE: false when the retrieved context lacks trial phase, endpoint definitions, or statistical results. This abstention behavior is intentional and should be respected in your application logic. Do not attempt to override it by loosening the constraints or removing the evidence-sufficiency check. If your use case requires answering from weaker evidence, use a separate prompt with appropriately lowered confidence thresholds and explicit caveats about source quality. Wire this prompt into a pipeline where a human reviewer can inspect abstentions and decide whether to broaden the retrieval or escalate the question.
Use Case Fit
Where this prompt works and where it fails. Understand the operational boundaries before deploying a clinical trial Q&A system.
Good Fit: Structured Trial Documents
Use when: querying well-structured clinical trial protocols, results databases (e.g., ClinicalTrials.gov), and adverse event reports with clear section headings. Guardrail: pre-process documents to extract trial phase, endpoints, and population metadata before retrieval to improve chunk alignment.
Bad Fit: Unstructured Patient Notes
Avoid when: the source material is free-text clinical notes, physician narratives, or unredacted patient records. This prompt expects structured trial data, not bedside documentation. Guardrail: route unstructured clinical text to a dedicated clinical note extraction prompt with PHI redaction before Q&A.
Required Inputs: Trial Metadata
Risk: answers lose critical context without trial phase, population demographics, and endpoint definitions. The model may conflate Phase I safety data with Phase III efficacy conclusions. Guardrail: always include trial metadata as a structured preamble in the retrieved context, not just raw text chunks.
Operational Risk: Statistical Overstatement
Risk: the model may present exploratory endpoints or subgroup analyses as primary findings without proper statistical context. P-values and confidence intervals can be quoted without multiplicity correction notes. Guardrail: add explicit instructions to label primary vs. secondary endpoints and flag unadjusted analyses. Implement post-generation validation that scans for p-values without context.
Operational Risk: Population Generalization
Risk: answers may silently generalize findings from a narrow trial population (e.g., adults 18-65) to broader groups (pediatric, elderly) without caveats. Guardrail: require the prompt to state population inclusion/exclusion criteria when presenting results. Add eval check for population scope disclosure.
Escalation Trigger: Missing Evidence
Risk: the system may fabricate trial results when retrieval fails to find relevant documents, especially for rare adverse events or unpublished data. Guardrail: configure the prompt to abstain explicitly when evidence is insufficient. Route abstained queries to a human researcher queue with the original question and retrieved context for manual review.
Copy-Ready Prompt Template
A reusable system prompt for generating grounded, cautious answers from clinical trial documents with explicit evidence scoping and uncertainty handling.
This template is designed to be pasted directly into your system prompt or user message template when building a Q&A system over clinical trial protocols, results, and adverse event reports. It enforces strict grounding in provided trial documents, separates primary from secondary endpoints, and requires statistical significance context and population limitation notes. The square-bracket placeholders let you inject the specific trial context, user question, and output constraints at runtime without modifying the core instruction set.
textYou are a clinical trial data assistant. Your only knowledge is the trial context provided below. You must not use any external knowledge about drugs, diseases, or medical facts. [TRIAL_CONTEXT] Answer the user question using only the information in the trial context above. Follow these rules exactly: 1. **Source grounding**: Every factual claim must be traceable to a specific passage in the trial context. If the context does not contain the answer, state that clearly rather than guessing. 2. **Trial phase context**: Identify the trial phase (Phase I, II, III, IV) from the context and note how it limits the generalizability of the findings. 3. **Endpoint separation**: Clearly distinguish between primary endpoints, secondary endpoints, and exploratory endpoints. Never present a secondary endpoint finding as if it were a primary endpoint result. 4. **Statistical reporting**: When reporting results, include p-values, confidence intervals, and effect sizes if present in the context. Note whether results reached statistical significance. If significance information is missing, state that it was not provided. 5. **Population limitations**: Explicitly note the inclusion/exclusion criteria, sample size, demographics, and any factors that limit generalizability to broader populations. 6. **Adverse events**: When discussing adverse events, report severity grades, frequencies, and attribution assessments exactly as stated in the context. Do not minimize or amplify safety signals. 7. **Uncertainty language**: Use precise uncertainty language. Distinguish between 'the trial demonstrated', 'the trial suggested', 'the data were inconclusive regarding', and 'the context does not address'. 8. **Abstention**: If the question asks for clinical advice, treatment recommendations, or off-label use, refuse to answer and state that you provide information retrieval only, not medical advice. User question: [USER_QUESTION] Output format: [OUTPUT_SCHEMA] Additional constraints: [CONSTRAINTS]
Adaptation notes: Replace [TRIAL_CONTEXT] with your retrieved trial documents, ensuring each chunk includes metadata about the trial phase, NCT number, and publication date. The [OUTPUT_SCHEMA] placeholder should contain your expected JSON structure or markdown format specification. Use [CONSTRAINTS] to inject domain-specific rules such as 'only use results from the final analysis, not interim analyses' or 'flag any sponsor-funded studies'. For regulated environments, add a [RISK_LEVEL] placeholder that gates whether the system should append a mandatory human-review disclaimer. Test this template with golden Q&A pairs where you know exactly which passages should be cited, and build an eval that checks for hallucinated statistics, missing population caveats, and endpoint conflation.
Prompt Variables
Required inputs for the Clinical Trial Data Q&A prompt. Each variable must be populated before the prompt is assembled and sent to the model. Missing or malformed variables are the most common cause of hallucinated trial metadata and incorrect endpoint attribution.
| Placeholder | Purpose | Example | Validation Notes |
|---|---|---|---|
[USER_QUESTION] | The natural-language question about a clinical trial, protocol, or result set | What was the primary endpoint for the KEYNOTE-024 trial and was it met? | Must be non-empty string. Check for ambiguous trial identifiers (e.g., 'the lung cancer study') and reject or request clarification before retrieval |
[RETRIEVED_DOCUMENTS] | Chunks from trial protocols, CSRs, adverse event tables, and registry entries returned by the retrieval step | Document 1: NCT02142738 protocol section 3.1... | Must contain at least one document with a trial identifier. Validate that document metadata includes source type (protocol, CSR, registry) and date. Reject retrieval sets with zero documents |
[TRIAL_PHASE] | The phase of the clinical trial being queried, used to scope statistical interpretation and safety context | Phase 3 | Must be one of: Phase 1, Phase 1/2, Phase 2, Phase 2/3, Phase 3, Phase 4. If unknown, set to 'Not specified' and add uncertainty caveat to output |
[PRIMARY_ENDPOINT] | The pre-registered primary endpoint extracted from the trial protocol or registry entry | Progression-free survival per RECIST v1.1 | Must be extracted from retrieved documents, not inferred. If multiple endpoints appear, flag ambiguity. Null allowed only if documents confirm no primary endpoint is defined |
[POPULATION_CONTEXT] | Key inclusion criteria and demographic scope of the trial population | Adults with previously untreated metastatic NSCLC, PD-L1 TPS ≥50%, ECOG 0-1 | Must be sourced from protocol eligibility section. If population differs across retrieved documents, flag the conflict. Required for any answer about generalizability |
[STATISTICAL_SIGNIFICANCE_THRESHOLD] | The pre-specified alpha level or significance boundary for the trial | 0.025 (one-sided) for primary endpoint | Extract from statistical analysis plan if available. If not found, default to 0.05 two-sided and note that the threshold is assumed, not confirmed. Required for any answer about whether an endpoint was met |
[CONFIDENCE_THRESHOLD] | Minimum confidence score required for the model to produce an answer rather than abstain | 0.85 | Float between 0.0 and 1.0. Answers with confidence below this threshold should trigger abstention or explicit uncertainty disclosure. Set based on risk tolerance of the consuming application |
Implementation Harness Notes
How to wire the Clinical Trial Data Q&A prompt into a production RAG application with validation, logging, and human review.
This prompt is designed to operate inside a Retrieval-Augmented Generation (RAG) pipeline where the model receives pre-retrieved clinical trial documents as [CONTEXT]. The implementation harness must ensure that the prompt receives clean, well-chunked, and metadata-rich context before generation. The application layer should handle document retrieval, chunk assembly, and metadata injection (trial ID, phase, sponsor, date) before populating the [CONTEXT] placeholder. The model should never be responsible for searching or selecting documents; it should only synthesize from what it is given.
Validation and Output Guardrails: After generation, the output must pass through a structured validation layer before reaching any user. Parse the model's response to verify that every claim tagged with a citation has a corresponding passage in the provided [CONTEXT]. Use a secondary LLM call or a deterministic string-match check to flag hallucinated citations. Validate that the output schema is respected: primary endpoints, secondary endpoints, statistical significance notes, and population limitations must be present as distinct sections. If the model fails to separate primary from secondary endpoints, or if it makes a claim without a source, route the output to a repair prompt or escalate for human review. Retries: If validation fails, implement a single retry with the original prompt plus the specific validation error message appended to [CONSTRAINTS]. Do not retry more than once for clinical use cases; escalate instead.
Model Choice and Tool Use: This prompt is optimized for models with strong instruction-following and long-context handling, such as GPT-4o, Claude 3.5 Sonnet, or Gemini 1.5 Pro. Do not use smaller open-weight models without extensive eval on hallucination rates for clinical text. The prompt does not require tool use or function calling during generation, but the harness should log every input, output, and validation result to an audit trail. For regulated environments, store the full prompt, retrieved context, model response, and validation report as an immutable record. Human Review Trigger: Any output that includes a statistical significance claim (p-value, confidence interval) or a comparative efficacy statement must be flagged for human review before it reaches an end user. The harness should block automated delivery of such outputs and route them to a review queue with the source documents attached.
What to Avoid: Do not use this prompt in a zero-context mode or with web search. The clinical domain requires grounding in specific, vetted trial documents. Do not allow the model to generate patient-specific advice or treatment recommendations; the prompt's scope is trial data Q&A, not clinical decision support. If a user question asks for medical advice, the harness should intercept it before generation and return a refusal message. Finally, do not deploy this prompt without a regression test suite that includes known hallucination-prone questions, missing-evidence scenarios, and edge cases where trials have conflicting results.
Common Failure Modes
Clinical trial Q&A prompts fail in predictable ways. These cards cover the most common failure modes and the specific guardrails that prevent them.
Statistical Significance Overstatement
What to watch: The model treats all reported results as equally reliable, failing to distinguish between primary endpoints with pre-registered analysis plans and exploratory subgroup analyses that may be underpowered or subject to multiplicity. It may report nominal p-values without context on correction for multiple comparisons. Guardrail: Require the prompt to classify each finding by endpoint type (primary, secondary, exploratory) and explicitly state whether multiplicity correction was applied. Add an eval check that flags any answer presenting exploratory findings without caveats.
Population Generalization Beyond Trial Scope
What to watch: The model applies trial conclusions to populations not represented in the study, ignoring inclusion/exclusion criteria, demographic skew, or geographic limitations. It may answer questions about pediatric or elderly populations using adult-only trial data without flagging the gap. Guardrail: Include a required output field for population applicability scope. Instruct the model to compare the query's implied population against the trial's enrollment criteria and explicitly state when the trial population does not match. Add a validator that detects unqualified generalization language.
Adverse Event Misattribution
What to watch: The model conflates adverse events that are temporally associated with treatment versus those with established causality. It may report all AEs as side effects without noting the investigator's causality assessment or the background rate in the control arm. Guardrail: Require the prompt to separate adverse events by causality grade (related, possibly related, unrelated) and always report control-arm rates alongside treatment-arm rates. Add an eval that checks for missing comparator context in safety claims.
Temporal Context Collapse
What to watch: The model answers using outdated trial data, ignores data-cut dates, or mixes results from different analysis timepoints (interim versus final) without labeling which snapshot each finding comes from. This is especially dangerous when interim results were later superseded. Guardrail: Include a required data-cut date field in the output schema. Instruct the model to cite the analysis timepoint for every numerical result and to flag when multiple data cuts exist. Add a retrieval filter that surfaces the most recent data-cut document first.
Endpoint Hierarchy Confusion
What to watch: The model treats all endpoints as independent, ignoring the hierarchical testing sequence where secondary endpoints are only tested if the primary endpoint is significant. It may report secondary endpoint significance as standalone findings without noting dependence on the primary outcome. Guardrail: Require the prompt to explicitly state the gatekeeping or hierarchical testing strategy when reporting secondary endpoint results. Add an eval that flags any secondary endpoint claim presented without context on whether the primary endpoint was met.
Cross-Trial Comparison Without Anchoring
What to watch: The model performs informal cross-trial comparisons when asked about relative efficacy or safety, ignoring differences in trial design, patient populations, endpoint definitions, and standard-of-care baselines. It may rank treatments numerically without noting that no head-to-head trial exists. Guardrail: Instruct the prompt to refuse indirect cross-trial comparisons unless the user explicitly requests them, and when provided, to require a structured table noting differences in design, population, endpoints, and time period. Add a refusal path for naive ranking requests.
Evaluation Rubric
Score each criterion as Pass, Fail, or Review before shipping the Clinical Trial Data Q&A prompt. Run these tests on a golden set of trial documents and questions with known answers.
| Criterion | Pass Standard | Failure Signal | Test Method |
|---|---|---|---|
Trial Phase Context | Answer explicitly states the trial phase (Phase I, II, III, IV) when available in source documents | Phase is omitted, guessed, or inferred from non-source context | Parse output for phase label; cross-check against source document metadata |
Statistical Significance Reporting | P-values, confidence intervals, or significance statements are quoted exactly from source with correct numeric values | Numbers are rounded, altered, or fabricated; 'significant' claimed without source support | Regex extract all numbers; diff against source document text |
Population Limitation Disclosure | Answer includes population demographics, inclusion/exclusion criteria, or sample size caveats when generalizing findings | Answer implies universal applicability without noting trial population constraints | Check for presence of population qualifier phrases; flag if missing when source contains demographic data |
Primary vs Secondary Endpoint Separation | Primary endpoints are explicitly labeled and distinguished from secondary or exploratory endpoints | Endpoints are conflated; secondary endpoint presented as primary; hierarchy flattened | Parse endpoint labels; verify against trial registration or protocol document endpoint classification |
Adverse Event Grounding | Adverse event mentions include frequency, severity grade, and attribution to treatment arm from source | Adverse events listed without frequency; severity omitted; causality implied without source support | Check each adverse event mention for frequency, grade, and attribution fields; flag missing elements |
Source Citation Completeness | Every factual claim links to a specific trial document section, table, or line | Claims lack citations; citations point to wrong sections; fabricated document references | Extract all claims; verify each has a citation; spot-check citation accuracy against source documents |
Uncertainty and Abstention | Answer explicitly states when source evidence is insufficient, conflicting, or absent; refuses to speculate | Answer fills gaps with plausible-sounding but unsupported statements; no 'unknown' or 'insufficient data' language | Check for abstention markers when source documents lack relevant information; flag unsupported assertions |
Human Review Trigger Compliance | Output includes a review flag when answering patient-specific, treatment-decision, or safety-critical questions | Answer provides direct clinical guidance without review flag; treats population-level data as individual advice | Scan for review-required markers; verify presence on all outputs touching treatment, dosing, or individual patient context |
Enabling Efficiency, Speed & Accuracy
Intelligent Analysis, Decision & Execution
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Talk to Us
Search across company data
Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.
Useful when people spend too long searching or get different answers from different systems.

Automate internal workflows
Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.
Useful when repetitive work moves across multiple tools and teams.

Add AI to products and internal tools
Build assistants, guided actions, or decision support into the software your team or customers already use.
Useful when AI needs to be part of the product, not a separate tool.
Adapt This Prompt
How to adapt
Start with the base prompt and a small set of trial documents (e.g., one protocol PDF and one results summary). Use a simple retrieval pipeline without strict schema enforcement. Focus on getting fluent, grounded answers before adding production guardrails.
Replace the [OUTPUT_SCHEMA] placeholder with a loose markdown structure:
code## Answer [answer text] ## Sources - [source citation]
Watch for
- Answers that sound authoritative but lack specific trial-phase or endpoint context
- Missing distinction between primary and secondary endpoints
- Statistical significance mentioned without p-values or confidence intervals from source
- No population-limitation flags when the trial cohort is narrow

About the author
Prasad Kumkar
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
Partnered with leading AI, data, and software stack.
How We Work
Custom AI workflows for your Business
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
01
Review the use case
We understand the task, the users, and where AI can actually help.
Read more02
Pick the right approach
We define what needs search, automation, or product integration.
Read more03
Build the first useful version
We implement the part that proves the value first.
Read more04
Improve from there
We add the checks and visibility needed to keep it useful.
Read moreThe first call is a practical review of your use case and the right next step.
Talk to Us